We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and Safety of Pyronaridine–Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar
Effectiveness and Safety of Pyronaridine-Artesunate for Treating Simple Malaria Caused by Two Parasite Types in Myanmar
AI simplified
Abstract
Adequate clinical and parasitological response (ACPR) was 100% at day 42 for pyronaridine-artesunate in both northern and southern Myanmar.
- Four clinical studies assessed the efficacy of pyronaridine-artesunate for treating uncomplicated malaria in Myanmar.
- A total of 196 patients with confirmed malaria received the treatment once daily for 3 days.
- Day-3 parasite clearance was observed in 96.9% of patients (190/196).
- Mutations in the Kelch propeller domain were detected in 39.0% of malaria isolates.
- No adverse events were reported, indicating that pyronaridine-artesunate was well tolerated.
AI simplified